PA
SEPN

PharVision Advisers’s Septerna Inc SEPN Stock Holding History

PharVision Advisers’s Portfolio SEPN Stock Details SEPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,739
Closed -$299K – 684
2025
Q4 		$299K Sell
10,739
-1,193
-10% -$28.5K 0.15% 274
2025
Q3 		$224K Buy
11,932
+1,780
+18% +$23.4K 0.13% 412
2025
Q2 		$107K Buy
+10,152
New +$83.6K 0.15% 250

Other funds holding SEPN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
TGV
TRV GP VI Boston, Massachusetts $136M AUM 328.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PharVision Advisers's SEPN Position: Q1 2026 in Review

PharVision Advisers sold out of Septerna Inc (SEPN) in Q1 2026, closing a stake of 10,739 shares — an estimated $299K sold.

PharVision Advisers first reported a position in SEPN in Q2 2025 and held it in 3 quarters. The position peaked at $299K in Q4 2025. 124 funds tracked by Wall St. Rank hold SEPN as of Q1 2026.

  • PharVision Advisers reported no remaining Septerna Inc position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 10,739 Septerna Inc shares in Q1 2026, an estimated $299K.
  • PharVision Advisers first reported a position in Septerna Inc in Q2 2025 and held it in 3 quarters.
  • PharVision Advisers's Septerna Inc position peaked at $299K in Q4 2025.
  • 124 funds tracked by Wall St. Rank held Septerna Inc as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.